Giant wins ArgiNox account

Share this article:

ArgiNox Pharmaceuticals, of Menlo Park, Ca named Giant Creative Strategy as the agency of record for their lead compound, tilarginine acetate. Tilarginine acetate is currently being studied in clinical trials for the treatment of cardiogenic shock. Giant will work with ArgiNox to develop an integrated scientific market preparation campaign, as well as naming and all branding and promotional materials for the product's impending launch.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.